Compare Bristol-Myers Squibb Co (BMY) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Twilio Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Twilio Inc trades at $246.7 (market cap $39.31B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.3× Twilio Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| BMY | TWLO | |
|---|---|---|
Market Cap | $129.94B | $39.31B |
Sector | Health | Technology |
52-Week High | $65.89 | $255.95 |
52-Week Low | $42.60 | $95.23 |
Enterprise Value | $163.92B | $37.72B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Twilio (TWLO) trades at $247.64, down 0.97% on the day but near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $1.47 actual vs. $1.32 expected, and raised full-year revenue growth guidance to 18-18.5%. Fundamentals show improving profitability, with net income margin reaching 20.62% in 2026, and positive cash flow trends.
The outlook is positive due to accelerating revenue growth and robust free cash flow generation, but risks include high valuation multiples like a P/E of 35.35 and competitive pressures in cloud communications. Analyst consensus is strongly bullish with a $266.31 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
